Donald Nicholson
President & Chief Executive Officer and Director

Mr. Nicholson holds a BCom Law degree (with Honors) in Business and Law from the University of Edinburgh.  Mr. Nicholson is a member of the Institute of Chartered Accountants of Scotland has more than 27 years of experience in the healthcare industry. Mr. Nicholson is, currently, the founding shareholder, and Chief Executive Officer of Mercuriali Ltd., a development stage United Kingdom private healthcare company. Prior to that, Mr. Nicholson was the founding shareholder and Chief Financial Officer of Stravencon Ltd., a European developer and marketer of generic pharmaceutical products manufactured in China. Prior to that he was Chief Financial Officer of SkyePharma Plc a UK specialty pharmaceutical company listed on the London market and on the US Nasdaq market. He was also a Director of SkyePharma Plc. Mr. Nicholson held a number of positions with Wellcome plc and Corange Ltd, the holding company of Boehringer Mannheim and DePuy, where he was corporate strategy and finance director. Mr. Nicholson has extensive experience in product and company acquisitions and disposals, in and out-licensing arrangements, sale/royalty agreements and financial strategy and funding structures. His industry experience includes Pharmaceuticals, Biochemicals, Orthopaedics, Diagnostics and Drug Delivery including Dermatology.

Sam Asculai
Chairman of Board and Chief Scientific Officer

Dr. Asculai, the holder of a Masters degree and a Ph.D. in Microbiology from Rutgers University, has more than 40 years of experience in the life science industry. Dr. Asculai is the inventor on over 50 U.S. patents, including over 30 patents related to hyaluronic acid, the cornerstone of Enhance Skin Products Inc.’s product line. Over the course of his career, Dr. Asculai has contributed to the development of products that have achieved cumulative sales of close to two billion dollars including, Monistat, Delfen Cream for herpes virus infectons, Ganciclovir, Solaraze, and MACI.

Immediately prior to his current role, Dr. Asculai was the sole owner of a private company whose assets form the basis for Enhance Skin Products Inc.’s operations. For ten years, Dr. Asculai served as Chief Executive Officer of Hyal Pharmaceutical Corporation where he developed the technology underpinning the Visible Youth™ brand. There he also invented and developed Solaraze a topical treatment for actinic keratosis, a precancerous skin condition that is commonly referred to as sunspots.

Dr. Asculai also held senior positions with Verigen AG, a tissue engineering company; ens Bio-Logicals ; Monsanto Corporation, a multinational agricultural biotechnology company; and the Ortho Pharmaceutical Corporation division of Johnson & Johnson, a multinational pharmaceutical company.

Drasko Puseljic
General Counsel

Mr. Puseljic is the holder of a B.Sc., Honours in Biology from McMaster University, an LL.B. from Osgoode Hall Law School and an M.B.A from the University of Toronto. He has held legal and/or business development roles at Hyal Pharmaceutical Corporation, Visible Genetics Inc., Verigen AG and Enhance Skin Products Inc., a private company whose assets are the basis for the Company’s operations. He also has investment banking experience with Eureka Capital Markets, a boutique investment bank. Currently, in addition to his role with Enhance Skin Products, Mr. Puseljic is a senior consultant with Kidd Consultants LLC, a firm providing financial and strategic consulting services internationally to life sciences companies.


Frode Botnevik

Mr. Botnevik is a partner of Management & Finance AS, a Norwegian financial consulting firm that provides services in the areas of project and export financing, structured finance, risk management, financial restructuring, strategic partners and mergers and acquisitions. Mr. Botnevik has over 30 years of experience of industrial and financial experience and has been involved in the process of listing companies on the Oslo and Singapore stock exchanges and on Nasdaq. Mr. Botnevik has served on the boards of directors of companies in more than twelve countries.

Monistat, Delfen, Solaraze and MACI are trademarks of their respective owners